Maybe you forgot this was also in the same blog from the consulting company that does not exist today:
"Brilacidin is certainly an interesting novel compound, coming from a new class, with a unique mode of action. It has great activity against Staph aureus and other Gram-positive pathogen (usually MIC90 ≤1 µg/mL) and has some very favorable characteristics.
The company informs us that the single dose brilacidin regimen was numerically non-inferior to the daptomycin comparator regimen administered for 7 days.[2] This is not all that surprising given brilacidin’s long half-life (approx. 20 hrs) and should be good news for the company. But how about the AE profile?
Good news here too: At the lowest dose level (0.6 mg/kg single dose), very few cases of hypertension were seen."
Many things have changed in the seven years since your blog was published:
"What do we really know about brilacidin / PMX-30063? Given the dearth of published information, and the total lack of peer-reviewed publications, the answer is: Really not much."
News 
Market Data 
Discover 
